Table 1.
Clinical and pathological characteristics of breast cancer patients referred to our BU
| Breast cancer lesions operated in March‐April 2019 (n = 93) | Breast cancer lesions during COVID‐19 pandemic (n = 63) | P‐value | |
|---|---|---|---|
| Patients’ age at diagnosis (years) | 58 (±15.5) | 61 (±13.8) | .16 |
| Neo‐adjuvant treatment | |||
| No | 83 (89%) | 58 (92%) | .56 |
| Yes | 10 (11%) | 5 (8%) | |
| Surgery a | |||
| Lumpectomy | 78 (84%) | 47 (69%) | .03 |
| Mastectomy | 15 (16%) | 21 (31%) | |
| SLNB a | |||
| No | 40 (43%) | 26 (38%) | .54 |
| Yes | 53 (57%) | 42 (62%) | |
| Postoperative stay (days) | 2.5 (±1.6) | 2.8 (±1.7) | .26 |
| Complications | |||
| Yes | 2 (2%) | 3 (5%) | .36 |
| No | 91 (98%) | 60 (95%) | |
| Histology a | |||
| Benign | 29 (31%) | 3 (4%) | <.00001 |
| DCIS | 6 (6%) | 3 (4%) | |
| CDI | 49 (53%) | 42 (62%) | |
| CLI | 9 (10%) | 20 (30%) | |
| pT stage a | |||
| pTIS/Benign lesions | 35 (38%) | 6 (9%) | .0003 |
| pT1 | 46 (49%) | 40 (59%) | |
| pT2 | 12 (13%) | 15 (22%) | |
| pT3 | 0 (0%) | 6 (9%) | |
| pT4 | 0 (0%) | 1 (1%) | |
| pN stage a | |||
| pN0/pNx | 74 (80%) | 54 (79%) | .98 |
| pN1‐2‐3 | 19 (20%) | 14 (21%) | |
| Indication for adjuvant CT | |||
| No | 74 (80%) | 24 (38%) | <.00001 |
| Yes | 19 (20%) | 39 (62%) | |
a
Values refer to total number of lesions n = 68. Five patients have bilateral breast cancer.